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The ‘Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular 
Carcinoma’ was prepared by the Study Group on New Liver Cancer Therapies established 
by the 'Research Project on Emergency Measures to Overcome Hepatitis' under the 
auspices of the Health and Labour Sciences Research Grant. The Guideline brings together 
data collected by the Study Group on the use and incidence of adverse events in 264 
patients with advanced HCC treated using sorafenib and in 535 patients with advanced 
HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as 
well as referring to the published studies, academic presentations, and reports from the 
private sector. The aim of this Guideline is to facilitate understanding and current thinking 
regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms 
of the format, the Guideline presents ‘clinical questions’ on issues pertaining to medical 
care, makes ‘recommendations’ on diagnosis and treatment in response to each of these 
clinical questions, and provides a rationale for these recommendations in the form of 




The molecular-targeted agent sorafenib has been found to significantly prolong 
survival in patient with hepatocellular carcinoma (HCC).1, 2) In May 2009, sorafenib was 
approved in Japan for unresectable HCC. Furthermore, miriplatin was approved in Japan 
for the treatment of HCC in January 2010, and clinical trials are also currently underway on 
a number of other promising new anticancer agents. Treatment of HCC is thus undergoing a 
period of major transition, but the role of these anticancer drugs and conventional therapies 
remains unclear, leading to concerns about the risk of serious AEs (SAEs). 
The Study Group on New Liver Cancer Therapies (the Study Group) was formed 
as part of the 'Research Project on Emergency Measures to Overcome Hepatitis' sponsored 
by the Health and Labour Sciences Research Grant, with the overall purpose of formulating 
a guideline to facilitate understanding on the practical usage of new anticancer drugs. 
The Study Group collected information on the use of new anticancer drugs, 
sorafenib and miriplatin at 16 affiliated institutions and compiled current opinions 
regarding the proper use of these drugs based on published studies, academic conference 
papers and reports from the private sector. These results have now been compiled in the 
form of a guideline. 
 However, it takes notice that this guideline is provisional and has been prepared to 
expedite the provision of proper information because information on these new anticancer 




I. Study methods, subjects and participating institutions 
A. Basic statistics 
 The Study Group's 'New Liver Cancer Therapies' (NLCT) study was based on data 
from patients with advanced HCC treated using sorafenib or miriplatin up until 22 
December 2010 at the participating institutions. Clinical data were recorded by each 
institution in case report files (CRFs) created by the Study Group. Of the patients enrolled 
in this study, 264 were treated with sorafenib and 535 were treated with miriplatin. Any 
input variables that were unclear were excluded from the analyzed data. After analyzing 
collecting data on the use of these drugs, the Study Group compiled current opinions on 
proper use based on published papers, academic conference papers and reports from the 
private sector. The Study Group proposed a series of ‘clinical questions’ (CQ) on issues 
pertaining to practical medical care and summarized the current evidence in response to 




The 16 institutions that participated in this study were: Kinki University; Chiba University; 
Yamaguchi University; Kurume University; Kyorin University; Showa University; Ehime 
University; Okayama University; Kyoundo Hospital; Tohoku University; Osaka University; 
Gifu University; Hyogo College of Medicine; Toranomon Hospital; Saitama Medical 




II-1 Sorafenib therapy 
II-1-1. Indications 
CQ1-1 
For whom patients with HCC is sorafenib therapy indicated? 
 
Recommendation 
Sorafenib therapy is indicated in HCC patients with good performance status (PS) and 
Child-Pugh class A for whom surgical resection, local ablation therapy (LAT), and 
transcatheter arterial chemoembolization (TACE) are not possible or not indicated. 
The safety and efficacy of sorafenib has not been established in Child-Pugh class B/C 
patients. 
Furthermore, the usefulness of sorafenib as adjuvant chemotherapy after resection, 
LAT, or TACE of HCC has not been demonstrated. 
 
Scientific statement 
 Two randomized, placebo-controlled trials demonstrating the usefulness of 
sorafenib were conducted on patients in whom surgical resection, LAT and TACE were not 
indicated or who were unresponsive to TACE.1, 2) 
 The Japan Society of Hepatology provides the following definitions for impossible 
and refractory cases to TACE.3) 
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Definition of “Impossible cases to TACE”  
 
1. Deterioration of treated vessel resulting in inability to select catheter for 
insertion into the nutrient vessel 
2. Deterioration in hepatic function to Child-Pugh class C due to repeated 
treatment 
3. Patients with tumor thrombus in main trunk or first branch of portal vein 
4. Patients with large arterio-portal shunts 
 
 
Definition of “Refractory cases to TACE”  
 
1) Intrahepatic lesion(s) 
(i) Poor Lipiodol® deposits (≤50%) observed on at least 2 
consecutive occasions in CT assessment of therapeutic response immediately 
after (>1 month) correctly performing TACE 
(ii) Multiple new lesions observed on at least 2 consecutive 
occasions in CT assessment of therapeutic response immediately after 
(>1month) TACE 
2) Appearance of vascular invasion 
3) Appearance of distant metastasis 
4) Tumor markers 
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Continued increase in tumor markers with transient decrease only immediately 
after TACE procedure 
 
 
  In the present NLCT study, as many as 91% of patients underwent prior treatment, 
in whom 29% received hepatic arterial infusion chemotherapy (HAIC). Comparison of the 
characteristics of the remaining NLCT study patients with those of previous clinical trials1, 2, 
4-6) is presented in Table 1. 
An adverse event (AE) report on all-patient special drug use surveillance (SDUS) 
conducted in Japan7) contains analysis and reporting of AEs for 777 patients for whom 
CRFs were collected up until 19 December 2009. 
That report compared the clinical characteristics for 51 of these 777 patients who 
died within 30 days of treatment ('early death group') and the 382 patients who survived for 
61 days ('control survival group'). The data indicate that the prevalence of Eastern 
Cooperative Oncology Group (ECOG) PS grades ≥2 tended to be high among patients in 
the 'early death group' at 5.9% compared to those in the 'control survival group' at 0.5%, 
suggesting the need to carefully follow the course of patients with poor PS. In the NLCT 
study, 98% of patients had a PS score of 0-1. 
 In terms of hepatic function, 2 randomized, placebo-controlled trials demonstrating 
the usefulness of sorafenib were conducted on Child-Pugh class A patients.1, 2) 
 Meanwhile, in the NLCT study, 81% of evaluable patients were Child-Pugh class 
A, and 94% had a Child-Pugh score of ≤7. Comparison of treatment results of Child-Pugh 
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class A and B patients did not reveal any difference in tumor control rates (46% vs. 50%; 
p=0.52), but overall survival (OS) was inferior in Child-Pugh class B patients (median OS: 
11.5 months vs. 5.2 months; p<0.01). 
 In a Phase I trial conducted in Japan, no clear increase in toxicity was observed in 
Child-Pugh class B patients compared to Child-Pugh class A patients.6) On the other hand, 
the aforementioned SDUS found that hepatic functional reserve was poor in the 'early death 
group' compared to the 'control survival group'.4) 
 A Phase II study of sorafenib therapy in HCC patients including those with 
Child-Pugh class B is currently underway in Japan (UMIN (University hospital Medical 
Information Network) 000002972). Another study currently being conducted worldwide is 
the Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its 
treatment with sorafenib (GIDEON); a large-scale prospective study on actual sorafenib 
therapy of patients with unresectable HCC. The GIDEON study is recruiting 3,000 patients 
from over 400 sites in more than 40 countries in the Asia-Pacific region, Europe, USA, 
Latin America, and Japan.8) The study's first interim analysis has been released and the 
findings of 511 recruited patients including those in Child-Pugh class B have been 
examined. No significant difference in grade 3 or 4 AEs was found to exist between 
Child-Pugh class A and B patients, at 31% and 38%, respectively.9) Future GIDEON study 
analyses are expected to provide crucial information concerning the safety of sorafenib for 
Child-Pugh class B patients. 
 A Phase III study of post-TACE adjuvant sorafenib chemotherapy versus placebo 
conducted in Japan and South Korea failed to demonstrate the usefulness of sorafenib 
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administration.10) In addition, a Phase III placebo-controlled trial of adjuvant sorafenib 
chemotherapy following radical treatment (either surgical resection or LAT) of HCC 
(STORM Trial) is currently underway.11)  
 The NLCT study did not include any patients treated with sorafenib as adjuvant 
chemotherapy. 
 
II-1-2 Method of Administration 
CQ1-2 
  What is the optimal dosage regimen for sorafenib therapy? 
 
Recommendation 
The standard dosage regimen for sorafenib therapy is 400 mg administered twice daily 
(800 mg/day). 
The safety and efficacy of sorafenib therapy in combination with other anti-neoplastic 
agents or TACE have not been established. 
 
Scientific statement 
 In the two aforementioned randomized, placebo-controlled trials demonstrating the 
usefulness of sorafenib, a single 400 mg dose of sorafenib was administered twice daily 
(800 mg/day), 1, 2) and usefulness was not observed at a reduced dosage. A high-fat diet 
reportedly lowers the plasma concentration of sorafenib so administration should be 
avoided from 1 hour before to 2 hours after meals. 
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Reduced dose regimen due to AEs was conducted in the above-mentioned studies 
as follows: 
 
      Step-down dose (step 1):  400 mg once a day 
      Step-down dose (step 2):  400mg every another day 
 
 In the NLCT study, 77% of patients received the standard dosage regimen of 400 
mg twice daily, while 21% were started on a reduced dose. 
 Comparison of the group started on the standard dose of 800 mg/day and the group 
started on a reduced dose did not reveal any significant differences in either duration of 
treatment (117 days vs. 81 days; p=0.05) or number of dosing days (107 days vs. 78 days; 
p=0.10). Furthermore, dosage was subsequently increased in 22% of the reduced initial 
dose group. Daily dosage intensity (DI) was 615 mg in the standard-dose group and 387 mg 
in the reduced-dose group. 
 It is conceivable to start sorafenib therapy at a reduced dose according to the 
condition of the patient or prevention of AEs. Because efficacy at reduced doses has not 
been demonstrated, as long as no AEs are encountered in the course of treatment, 
consideration should be given to increasing the dose to the standard dosage regimen. 
 With regard to sorafenib combination therapies, Phase I and Phase II studies on 
systemic chemotherapy in combination with sorafenib therapy have been published for 
radiotherapy,12, 13)doxorubicin,14)tegafur/uracil,15) and octreotide.16) Several Japanese 
clinical trials are also being conducted on combination therapy, specifically low-dose 
 13 
cisplatin/fluorouracil HAIC (UMIN000004315), cisplatin HAIC (UMIN000001496), and 
S-1 chemotherapy (UMIN000002418, UMIN000002590). Therapies combining sorafenib 
with other anti-neoplastic agents are therefore still in the research stage, and their efficacy 
is yet to be demonstrated. 
 In terms of sorafenib combined with LAT, a Phase III placebo-controlled trial of 
adjuvant sorafenib chemotherapy following radical treatment (surgical resection or LAT) of 
HCC (STORM Trial) is presently underway.11) Meanwhile, sorafenib combined with TACE 
has been investigated in a Phase III study of post-TACE adjuvant sorafenib chemotherapy 
versus placebo conducted in Japan and South Korea, but the study failed to demonstrate the 
usefulness of sorafenib administration.10)Another Phase II trial on TACE in combination 
with sorafenib is presently being carried out in Japan (TACTICS; UMIN 000004316). 
 
II-1-3 Discontinuation Criteria 
CQ1-3 
How and when should sorafenib therapy be discontinued? 
 
Recommendation 
Administration of sorafenib should be discontinued immediately in the event of SAEs. 
Discontinuation should also be considered when disease progression is confirmed by 




 In the two randomized, placebo-controlled trials demonstrating the usefulness of 
sorafenib therapy, administration was discontinued upon confirmation of radiologic or 
symptomatic progression or in the event of SAEs. 1, 2) 
 In the NLCT study, sorafenib therapy was discontinued in 185 patients with 63% 
due to disease progression and 22% due to AEs. Moreover, 60% of discontinued patients 
did not undergo post-treatment. 
 No data are currently available on the efficacy/safety of continued administration 
of sorafenib after disease progression. 
 
II-1-4 Adverse events 
CQ1-4 
  What are the adverse events associated with sorafenib therapy? 
 
Recommendation 
Some form of AE has appeared in almost all patients treated with sorafenib. 
These AEs vary, and have even included serious adverse events (SAEs) resulting in 
death. Familiarity with these AEs is therefore essential, to carefully monitor patient 
progress while taking the necessary precautions, and to respond rapidly when an AE 
occur. 














 While infrequent, life-threatening SAEs include hepatic failure, interstitial pneumonia, 
and gastrointestinal hemorrhage. 
 In addition, the following blood test abnormalities are known to occur frequently in 







5. Hepatic impairment (elevated AST/ALT/ALP/-GTP) 
6. T-Bil elevation 
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7. Amylase elevation 




 AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline 
phosphatase, -GTP; gamma-glutamyltransferase, T-Bil: total bilirubin 
 
Scientific statement 
 The incidence of sorafenib-related AEs was 80% in the SHARP trial and 81.9% in 
the Asia-Pacific trial. Frequently occurring AEs were HFSR, rash/desquamation, diarrhea, 
anorexia, hypertension, fatigue, alopecia, and nausea. 1, 2) 
 Sorafenib-related AE incidence in the NLCT study was 87%, of which 36% were ≥ 
grade 3 AEs. While incidences of HFSR, diarrhea and alopecia in the NLCT study were 
similar to those of the Asia-Pacific trial2) and SDUS,17) incidences of rash/desquamation, 
anorexia, hypertension and fatigue were slightly higher in the present study (Table 2). 
 Evaluation of changes in clinical laboratory data was achieved by examining the 
CRFs to find the largest variations during sorafenib therapy, as well as the test date on 
which variations occurred. Consequently, the frequency of abnormal values in the NLCT 
study differed from those of the SHARP trial1)and SDUS17) (Table 3). 
 Changes in laboratory values were seen in 96% of the sorafenib group, with 64% 
showing an AE ≥ grade 3. Incidence of diminished blood cell counts was high compared to 
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previous studies, with thrombocytopenia, leukopenia, neutropenia, and anemia seen in 56%, 
43%, 37%, and 34% of the sorafenib group, respectively.  
 Hepatic impairment was also frequent, with elevated AST and ALT occurring in 
≥50% of sorafenib-treated patients (70% and 55%, respectively), of whom a further 25% 
and 15% had AST and ALT readings ≥grade 3, indicating levels exceeding 200 IU/L after 
commencement of treatment. Similar results were observed for ALP and -GTP. Elevated 
T-Bil was seen in 53% of the sorafenib group, of whom 11% had readings that were ≥grade 
3, which is more than 3 times the upper limit of normal (ULN). 
 Increased amylase was seen in 49% of the sorafenib group, of whom 12% had 
levels ≥grade 3, which is more than twice the ULN. In terms of electrolyte abnormalities, 
hyponatremia and hypokalemia were observed in 50% and 25% of the sorafenib group, 
respectively. Hypocalcemia and hypophosphatemia were also seen in ≥50% of the sorafenib 
group, but the valid response rate was low for these variables. 
 Hypoalbuminemia was seen in 48% of the sorafenib group, of whom only 5% had 
readings <2.0 g/dL. 
No significant difference was seen in AE incidences for Child-Pugh class A and B 
patients, at 88% and 83%, respectively (p=0.53). The incidence of AEs ≥grade 3 was also 
insignificant between Child-Pugh class A and B patients (35% vs. 39%, p=0.76). 
Similar comparisons for sorafenib group patients with Child-Pugh class A scoring 
5 and 6 also did not reveal any significant differences in either total incidence of AEs at 
89% and 88%, respectively (p>0.99), or in the incidence of AEs ≥ grade 3, at 35% each 
(p>0.99). 
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Incidence of abnormal laboratory data also did not vary significantly among 
Child-Pugh class A and B patients, at 96% and 95%, respectively (p>0.99). Similarly, no 
significant difference was observed in the incidence of abnormal laboratory data ≥grade 3, 
at 63% and 66% of class A and B patients, respectively. Performing the same comparisons 
for sorafenib group patients with Child-Pugh class A scoring 5 and 6 also failed to reveal 
any significant differences either in total incidence of abnormal laboratory values (97% and 
95%, respectively; p>0.80) or in the incidence of abnormal laboratory data ≥ grade 3 (58% 
and 68%, respectively; p>0.26), despite a higher percentage for patients with Child-Pugh 
score 6. 
 
II-1-5. AE management 
CQ1-5 
What measures should be taken in management to sorafenib-related AEs? 
 
Recommendation 
Preventative measures and careful monitoring of the patient are required for frequently 
occurring AEs such as HFSR, hypertension, and hepatic impairment. 
Patients undergoing sorafenib therapy often experience AEs soon after beginning of 
treatment. Careful monitoring of the patient by carrying out blood test and medical 





 The NLCT study investigated measures taken in management to sorafenib-related 
AEs (Table 4). Management to HFSR was common, with topical application of emollients 
performed most frequently (69%), and followed by topical application of steroids (38%) 
and consultation to a dermatologist (24%). An increased dose of hypotensive drugs was 
prescribed in 21% of patients, while diarrhea was treated with antiflatulent and 
anti-diarrheal drugs in 19% and 16% of patients, respectively. Antiemetic agents were 
administered in 5% of patients. 
 Most AEs observed in the NLCT study, including abnormal laboratory values, 
occurred early at up to 8 weeks after initiating sorafenib therapy. For this reason, careful, 
early monitoring of the patient is essential. Bayer Yakuhin's "Nexavar Proper Use 
Guidelines"7) recommends that a battery of tests be performed regularly or as required 
during sorafenib therapy (Table 5). Educating patients to withhold taking the drug and 
consult their doctors immediately if they begin to feel unwell early in the treatment is 
another important way to prevent AEs from becoming severe. 
 SAEs should generally be handled by immediately withholding administration or 
reducing the dose, and reinstitution of treatment or dose increase can be considered if the 
patient recovers. 
 Provided below is a summary of management to prevent and respond to major 
sorafenib AEs. 
 
 Hand-foot skin reaction (HFSR) 
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Prevention: HFSR occurs most frequently in areas affected by hyperkeratosis and 
induration. Risk factors for HSFR include physical stimulation of the skin such as 
compression, heat or friction, so the patient's hands and feet should always be 
inspected before treatment. Any thickening of the stratum corneum should be 
removed and the patient instructed to cover and bathe the affected areas to prevent 
physical stimulation. An emollient containing urea or salicylic acid should be 
applied to the hands from 1-2 weeks before commencing therapy17). 
 
Management: Minor, painless skin changes such as erythema can be treated with steroid 
ointment without reducing or discontinuing sorafenib therapy. If further 
deterioration such as formation of blisters occurs, the dosage should be reduced. If 
the condition interferes with the patient's activities of daily living due to ulcers, 
cracking or pain etc., the therapy should be withheld and the patient consulted to a 
dermatologist as necessary. If the condition improves after withholding the 
sorafenib, therapy can be resumed at a reduced dose, and can subsequently be 
increased on the basis of the AE condition. 
 Hepatic impairment, hepatic failure and hepatic encephalopathy 
Prevention: Sorafenib therapy should be avoided in patients with severe liver impairment; 
particularly those with AST and ALT levels exceeding 200 IU/L. 
 
Management: The patient should be carefully monitored by performing medical 
examinations and hepatic function tests once weekly for the first month of 
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treatment, once fortnightly for the next 3 months, and once monthly thereafter. 
Reducing, withholding, or discontinuing sorafenib therapy should be considered if 
the patient exhibits symptoms of hepatic failure including hepatic encephalopathy 
and ascites or a sudden increase in AST and ALT levels. Immediate suspension of 
therapy and careful in- or outpatient monitoring is recommended if the patient's 
AST and ALT levels increase beyond 200 IU/L or if T-Bil exceeds 3.0 mg/dL7). 
Treatment can be resumed after the patient recovers and increased on the basis of 
the AE condition. 
 
 Diarrhea 
Prevention: Patients should refrain from eating foods and beverages that contain a lot of 
spices, fat, or caffeine. Laxatives and dietary fiber supplements should also be 
avoided. 
 
Management: If frequency of defecation increases to 3 times/day, intestinal drugs such as 
bifidobacterium powders and albumin tannate, and anti-diarrheal drugs such as 
loperamide and cholestyramine should be administered.18) In addition, the patient 
should be instructed to drink fluids to prevent dehydration. Reducing, withholding, 
or discontinuing sorafenib therapy should be considered if the frequency of 
defecation increases to ≥4 times/day and the patient exhibits symptoms of 
dehydration. Dehydration symptoms should be managed systemically with fluid 
replacement, etc. Treatment can be resumed after the patient recovers and 
 22 
subsequently increased on the basis of the AE conditions. 
 
 Hypertension 
Prevention: If hypertension is observed prior to sorafenib therapy, systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) should be controlled to ≤140 mmHg and 
≤90 mmHg, respectively. 
 
Management: Patients should be instructed to measure home blood pressure during the 
early treatment period. If elevated blood pressure (BP) is observed, hypotensive 
drugs should be administered or the dosage increased. Calcium antagonists and 
angiotensin receptor blockers (ARBs) are commonly used as hypotensive agents. A 
single drug is typically administered to begin with, and other types of hypotensive 
drugs may be co-administered if the reduction in BP is insufficient. Regardless of 
therapy, administration of sorafenib should be withheld if SBP is ≥180 mmHg or 
DBP is ≥110 mmHg. Treatment can be resumed after the patient recovers and then 
increased on the basis of the AE conditions. 
 
 Amylase elevation 
Management: Increases in amylase are usually transient and gradually subside even when 
sorafenib therapy is continued. However, some cases of pancreatitis has previously 
been reported in patients treated with sorafenib, so if the patient has abdominal 
pain or other symptoms suggestive of pancreatitis, or elevated amylase levels are 
 23 
sustained, sorafenib therapy should be withheld and imaging procedures such as 
dynamic CT performed to determine whether pancreatitis is present.7)  
 
 Interstitial pneumonia 
Management: Interstitial pneumonia should be suspected and sorafenib therapy 
discontinued immediately in patients exhibiting clinical symptoms such as dyspnea, 
dry cough and fever, and lung crepitation or reduced SpO2 (percutaneous oxygen 
saturation) on physical examination. In addition, diagnosis and proper treatment 
should be carried out based on prompt diagnostic imaging such as chest X-ray or 
high-resolution chest CT (HRCT) and blood tests such as KL-6 after consulting 
with a respiratory specialist.7)  
 
II-1-6. Evaluation of therapeutic response 
CQ1-6 
How and when should therapeutic response of sorafenib be evaluated? 
 
Recommendation 
The antitumor effects of sorafenib therapy are normally evaluated by diagnostic 
imaging with dynamic CT or dynamic MRI and subsequent measurement of tumor size 
based on a single cycle of 4-6 weeks of sorafenib administration. 
Changes in intra-tumoral blood flow are often seen following sorafenib therapy, so 
evaluation can also be performed by measuring the area of tumor staining in addition to 
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tumor size.  
AFP (alpha-fetoprotein) and PIVKA-II (DCP) (protein induced by vitamin K absence 
or abnormality, des-gamma-carboxyprothrombin) tumor markers are also typically 
evaluated in conjunction with tumor images at cycles of 4-6 weeks. 
Elevated PIVKA-II (DCP) concentrations during sorafenib therapy may not always be 
due to disease progression. Consideration should also be given to evaluation of tumors 
in patients for whom treatment was interrupted due to AEs.  
 
Scientific statement 
 In the two randomized, placebo-controlled trials demonstrating the usefulness of 
sorafenib therapy, 1, 2) therapeutic response to sorafenib was evaluated every 6 weeks on the 
basis of diagnostic imaging. 
 In the NLCT study, median overall survival (OS) was 10.8 months, 6-month 
survival rate was 65%, 1-year survival rate was 45%, and median progression-free survival 
(PFS) was 2.1 months (Fig. 1). Comparison of efficacy evaluation findings with those of 
previous clinical trials1, 2, 5)are presented in Table 6. 
 Reductions in intra-tumoral blood flow are often observed with sorafenib therapy, 
so instead of simply evaluating tumor size based on the conventional Response Evaluation 
Criteria in Solid Tumors (RECIST), the use of therapeutic response criteria for evaluating 
intra-tumoral necrotic regions such as modified RECIST19) or the Response Evaluation 
Criteria in Cancer of the Liver (RECICL)20) has recently been advocated.21, 22) Even if the 
size of the tumor has slightly increased, therapy may be deemed effective and subsequently 
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continued if the area of reduced intra-tumoral blood flow has increased.  
 Previous studies have reported that PIVKA-II (DCP) expression is induced in 
hypoxic HCC cells following sorafenib therapy23) and that elevated PIVKA-II (DCP) 
concentrations may act as surrogate markers for HCC tissue ischemia.24) However, elevated 
PIVKA-II levels are also seen in disease progression, so care should be taken during 
assessment of therapeutic response. 
 According to the NLCT study data, therapeutic response was not evaluated in 20% 
of sorafenib group patients. However, short-term administration of sorafenib was found to 
inhibit tumors in some patients on whom therapy was interrupted due to AEs, suggesting 
that regular tumor assessment should also be considered for patients with interrupted 
treatment.  
 
II-1-7. Continuation of therapy 
CQ1-7 
How long sorafenib therapy should be continued? 
 
Recommendation 
Sorafenib therapy should preferably be maintained until clear disease progression is 
determined on evaluation of therapeutic response.  
If clear disease progression is not identified in diagnostic imaging, therapy may be 
continued after considering the risks and benefits. 
No data are currently available on the efficacy/safety of continued sorafenib 
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administration after disease progression has been confirmed. 
 
Scientific statement 
 In the NLCT study, 31% of patients in the sorafenib group underwent some form 
of additional treatment after completion of the therapy. Specifically, 12% underwent TACE, 
8% underwent systemic chemotherapy, 7% underwent HAIC, 4% underwent radiotherapy, 
and 2% underwent hepatectomy/LAT. 
 Progressive disease (PD) was confirmed in 165 patients in the sorafenib group 
during the study's observation period, of whom a further 23 patients (14%) underwent 
continued oral administration of sorafenib for ≥1 month after PD confirmation. Comparison 
of these 23 patients with those in whom therapy was discontinued did not reveal any 
significant differences in OS, and no data are currently available regarding the 
efficacy/safety of continued sorafenib administration after confirmation of PD.  
 
II-1-8. Predictors of therapeutic efficacy 
CQ1-8 
What are the predictors of therapeutic efficacy for sorafenib therapy? 
 
Recommendation 
Clear predictors of therapeutic efficacy for sorafenib have yet to be established, but the 
number of intrahepatic lesions and pretreatment levels of tumor markers (AFP, 




 A study of biomarkers in patients treated with sorafenib has suggested the efficacy 
of sorafenib is associated with low serum HGF and high c-KIT levels at baseline.25) 
Efficacy of sorafenib has also been linked to high levels of ERK expression in tumor 
tissue.25, 26) However, these reported associations cannot yet be described as established 
predictors of efficacy, and biomarkers are currently searching in some prospective clinical 
trials using sorafenib. 
 The current results indicate that early AFP response is a useful surrogate marker to 
predict treatment response and prognosis in patients with advanced HCC who receive 
anti-angiogenic therapy.27)  
 In an attempt to identify predictors of therapeutic efficacy for sorafenib, the NLCT 
study examined baseline patient characteristics (age, sex, BMI (body mass index), 
ECOG-PS (Eastern Cooperative Oncology Group – performance status) , hepatic functional 
reserve, prior treatment, cause of hepatic impairment, clinical laboratory values) and tumor 
factors (presence or absence of intrahepatic/extrahepatic lesions, maximum tumor size, 
vascular invasion, stage), and consequently found that tumor control rates tended to be 
higher in patients with <5 intrahepatic lesions compared to those with ≥5 lesions (54% vs. 
40%, respectively; p=0.058). In addition, the tumor control rate was significantly higher in 
patients with a baseline AFP value <10 ng/mL compared to those with values ≥10 ng/mL 
(68% vs. 43%, respectively; p=0.021). The tumor control rate also tended to be higher in 
patients with baseline PIVKA-II (DCP) value <40 mAU/mL than in those with a value of 
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≥40 mAU/mL (60% vs. 42%, respectively; p=0.051) (Table 7). 
 
 




Is miriplatin a platinum preparation that can be used on renal disorder patients? 
 
Recommendation 
Renal disorder patients can be treated using miriplatin as long as they are capable of 
undergoing angiography (serum Cre (creatinine) level <2.0 mg/dl) and as long as 




 Miriplatin remains in the tumor together with Lipiodol®, where it slowly releases 
platinum compounds. This agent is thus believed to gradually increase serum platinum 
concentration with minimal adverse effect on renal function. 
 In a randomized phase II trial comparing miriplatin and zinostatin stimalamer 
(SMANCS®) in patients with normal serum Cre levels, renal dysfunction indicated by  
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serum Cre level >1.5 mg/dl was observed in only 2.4% of patients in the miriplatin 
treatment group (Table 8) .28)  
 In the NLCT study, median serum Cre prior to miriplatin therapy was 0.8 mg/dl 
(range, 0.4-10.5 mg/dl), of which patients with a serum Cre level >1.0 mg/dl accounted for 
17.7%. Median serum Cre after treatment was 0.8 mg/dl (range, 0.1-12.6 mg/dl), which was 
unchanged from baseline, and 94.7% of patients experienced an increase of ≤0.5 mg/dl 
(Table 11). Only 1.8% of patients exhibited renal dysfunction ≥grade 3 as indicated by 
serum Cre level >3 mg/dl.  
 Analysis of patients with baseline serum Cre <2.0 mg/dl shows that just 2.5% of 
patients increased serum Cre >0.5 mg/dl, and no more than 0.6% of patients experienced 
renal dysfunction ≥grade 3 (Table 11). 
In addition, no serious renal dysfunction was observed after miriplatin 
administration in patients with serum Cre levels around 2.0 mg/dl. 
 Based on these findings, the Study Group considers that miriplatin therapy can be 
administered without instigating renal dysfunction in patients with serum Cre <2.0 mg/dl 
who are capable of undergoing angiography. 
 However, transcatheter arterial infusion (TAI)/TACE with miriplatin 
simultaneously uses an iodinated contrast medium with drugs that can cause renal 
dysfunction such as anti-inflammatory analgesics to treat post-operative fever. Sufficient 
consideration should therefore be given to the risk of drug-induced renal dysfunction, and 





Can miriplatin be used safely in patients with Child-Pugh class B? 
 
Recommendation 
Miriplatin can be used to treat these patients without causing serious complications. 
Furthermore, no demonstrable difference in the antitumor effects of miriplatin has been 
observed between Child-Pugh class A and B patients. 
 
Scientific statement 
 The NLCT study included 281 Child-Pugh class A and 144 Child-Pugh class B 
patients. In Child-Pugh class B patients, the only SAEs ≥grade 3 were fever and anorexia, 
at incidences of 0.7% each, with no cases of ascites or hepatic failure ≥grade 3 (Table 12). 
In a study of TAI with miriplatin, in 17 Child-Pugh class B patients, no significant 
differences were seen in pre- or post-treatment 15-min retention rates of indocyanine green 
(ICG15), and no SAEs or increased ascites or hepatic failure necessitating additional therapy 
or prolonged hospitalization were observed.29) 
 Although the retrospective analysis of the NLCT study coupled with differences in 
characteristics of Child-Pugh class A and B patient effectively precludes simple 
comparisons of these patients, no significant differences in respective AE incidences were 
seen, apart from a higher frequency of fever and thrombocytopenia ≥grade 3 among 
Child-Pugh class B patients (Tables 12, 13).  
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  In terms of evaluation of antitumor effects according to the RECICL proposed by 
the Liver Cancer Study Group of Japan, the present study did not reveal any significant 
differences in therapeutic responses of Child-Pugh class A and B patients (Table 14), while 
50% of Child-Pugh class B patients in the aforementioned study of TACE with miriplatin 
achieved a treatment effect (TE) of 'TE3' or 'TE4', in which tumor was controled.29)  
 
CQ2-3 
Is miriplatin effective against cisplatin-resistant HCCs? 
 
Recommendation 




 Miriplatin is classified as a third-generation platinum drug and a basic research on 
the drug suggested potential activity in cisplatin-resistant HCCs because cisplatin-resistant 
HCC cell lines did not show cross-resistance to miriplatin.30)  
 A Japanese Phase I trial combining miriplatin and TAI using Lipiodol® (Lip-TAI) 
on HCC refractory to cisplatin/Lip-TAI has reported a treatment success rate of 18.2%.31) 
However, the study was conducted on a small patient population, so the usefulness of this 
therapy is yet to be established and future studies are awaited.  
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 Furthermore, no data are currently available regarding the efficacy of miriplatin 
therapy in patients who are unresponsive to TAI/HAIC using cisplatin. 
 
II-2-2. Method of administration 
CQ2-4 
What are the effects and AEs of combining embolic materials with miriplatin? 
 
Recommendation 
Combination therapy of embolic materials and miriplatin is expected to improve 
antitumor effects comparing to miriplatin alone, but there is currently insufficient 
evidence to support this. 
AEs associated with combination therapy of embolic materials and miriplatin may not 
differ noticeably from those of conventional TACE therapy using epirubicin. 
 
Scientific statement 
 Compared to stand-alone therapy, the combination of embolic materials in the 
hepatic arterial catheterization treatment is generally considered to deliver enhanced 
antitumor effects based on its blood flow blockage effect,32)so treatment combined with 
embolic materials are mostly selected for the treatment of HCC. However, Phase I and II 
trials using miriplatin have opted not to use embolic materials in combination with 
miriplatin.31, 33)  
 Meanwhile, two studies on miriplatin used in combination with embolic material s 
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on small number of patients have reported high rates of treatment success, with TE3 and  
TE4 scores obtained in 60.0-77.7% of patients.29, 34) 
 In the NLCT study, embolic material was used in combination with miriplatin on 
473 patients (88.4%). Simple comparison of patients undergoing miriplatin/embolic 
material combination therapy and those who underwent miriplatin alone therapy was not 
possible due to the retrospective nature of this study, as well as the different patient 
characteristics of the respective treatment groups. However, antitumor effects were higher 
in the miriplatin/embolic material therapy group than in the miriplatin therapy group, at 
49% and 31%, respectively (Fig. 2). Analysis of independent factors contributing to the 
achievement of TE3/4 scores in TAI/TACE therapy using miriplatin showed that the use of 
embolic material had a higher risk ratio of 3.66 (p<0.001) (Table 15). 
 A Phase III trial of TACE using miriplatin is currently underway, and the results 
will likely be useful in investigating the efficacy of using miriplatin in combination with 
embolic materials. 
 In the NLCT study, patients who underwent combination therapy with embolic 
material showed a high incidence of fever, suspected to be due to post-embolization 
syndrome. Although high incidences of hematological AEs neutropenia and elevated AST 
were seen, no significant differences were identified in the incidences of most AEs, and no 
serious complications such as hepatic failure or ascites were observed (Tables 16, 17). 
 Similarly, a small pilot study (Phase II clinical trial) on miriplatin combined with 
an embolic material found some mild complications, but none of a serious nature.34) 




Is standard hydration required prior to administration of miriplatin? 
 
Recommendation 
Standard hydration is not required except in the case of renal failure. 
 
Scientific statement 
 Sufficient hydration before and after administration of cisplatin (IA-call®, Nippon 
Kayaku, Tokyo, Japan) used in HAIC is necessary to prevent nephrotoxicity. 
 Miriplatin is highly soluble in Lipiodol® and remains in tumor with Lipiodol®, 
where it continuously releases platinum compounds.35) So only a small amount enters 
systemic circulation expecting to reduce systemic AEs, including renal dysfunction. 
 As stated in CQ1, the impact of miriplatin on renal function is considered to be 
mild. Two of the aforementioned Phase II trials did not perform pre-treatment hydration to 
prevent renal impairment.28, 29)In the NLCT study, patients with advanced renal 
insufficiency were excluded and no serious renal impairment occurred in patients treated 
with miriplatin without prior hydration. 
 
 
II-2-3. Adverse events 
CQ2-6 
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What are the adverse events associated with miriplatin therapy? 
 
Recommendation 
Post-embolization syndrome characterized mainly by fever is often seen, and biphasic 
fever is relatively infrequent. Incidences of nausea and vomiting are also low compared 
to other platinum agents. Complications such as ascites, liver abscess, biloma, and 
dyspnea have incidences of about 1%.  
  
Scientific statement 
 In the NLCT study, post-embolization syndrome was observed in ≥90% of patients 
treated with miriplatin. However, the incidence of biphasic fever, which is said to be a 
characteristic AE associated with miriplatin, was low at 2.8% (Table 9). 
 Incidences of nausea and vomiting were low compared to other platinum agents, at 
18.8% and 13.5%, respectively. 
 Hematological AEs were leukopenia at 38.2%, thrombocytopenia at 32.1%, and 
neutropenia at 20.1%. Incidence of eosinophilia, which is also reported as a characteristic 
AE of miriplatin, was relatively low at 14.6% (Table 8). 28, 33, 34) 
 Abnormal hepatic function was frequent, with elevated AST and ALT occurring in 
49.9% and 78.4% of patients, respectively, of whom a further 12.4% and 26.6% had 
respective AST and ALT values ≥grade 3. Elevated T-Bil was seen in 31.6% of patients, of 








Typically, no deterioration is seen in post-operative ICG15, but prothrobmin time (PT) 
ratio (%) may display a transient decline.  
 
Scientific statement 
  Hepatic impairment after miriplatin administration has been reported to peak 
within 2 weeks in 46% of patients, at 3-5 weeks in 23% of patients, and at 9-11 weeks in 
31% of patients.33) 
  The NLCT study also found that in evaluable patients, ICG15 values had not 
deteriorated at 1-2 weeks after therapy and that PT ratio (%) exhibited a transient decline, 
but subsequently recovered in the majority of patients. 
  Child-Pugh class B patients did not find any significant differences in pre- or 
post-treatment ICG15, and did not find any SAEs or increased ascites or hepatic failure 
necessitating additional therapy and prolonged hospitalization.31) 
  However, the safety of miriplatin used in combination with embolic materials has 
yet to be established, and a Phase III study on concomitant use of miriplatin and embolizing 




Does vascular injury occur after intra-arterial administration of miriplatin? 
 
Recommendation 
Vascular injuries such as hepatic artery occlusion, arterial stenosis and arterioportal 
shunts, and hepatic lobar atrophy caused by vascular damage are rare. 
  
Scientific statement 
 No reports have described vascular injuries from non-hematological toxicity in 
previous Japanese Phase I and II trials on miriplatin therapy.31, 33) Likewise, no vascular 
injuries have been reported in the NLCT study (Table 9). In TAI without the use of embolic 
materials, the aforementioned randomized phase II trial comparing miriplatin and zinostatin 
stimalamer (SMANCS®) found that vascular injuries occurred in 48.4% of the SMANCS® 
treatment group (n=31), but that no vascular injuries occurred in the miriplatin treatment 
group (n=73).28) In a limiting study performing follow-up angiography on 9 patients at 2-6 
months after treatment, no arterial stenoses, arterial occlusions, or arterioportal shunts were 
observed.29) 
 
II-2-4. Evaluation of therapeutic response 
CQ2-9 




Non-specific accumulation of Lipiodol® appears on dynamic CT at 1 week after 
administration of miriplatin, so evaluation of therapeutic response should preferably be 
performed at 4-8 weeks after administration. 
 
Scientific statement 
 Evaluation of therapeutic response performed at 1 day or 1 week after starting 
miriplatin therapy may result in overestimation of response due to the appearance of 
non-specific Lipiodol® deposits. Evaluation of therapeutic response using dynamic CT at 
4-8 weeks after therapy is therefore preferable, to allow these non-specific deposits to 
disappear. In the above-mentioned Phase I clinical trial, therapeutic response to miriplatin 
was evaluated with dynamic CT at 1 week, 5 weeks, and 3 months after therapy,27) while 
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phase II5)  
(n=137) 
 % % % % % 
Age (years)       
Median 70  64.9±11.2 51 69 
Range 33-87  (mean±SD) 23-86 28-86 
Gender      
Male 79  87 84.7 71 
PS      
0 83 69.5 54 25.3 50 
1 15 26.5 38 69.3 50 
Child-Pugh class      
A 81 88.2 95 97.3 72 
B 19 9.9 5 2.7 28 
HBs antigen      
Positive 20 24.6 19 70.7 17 
HCV antibody      
Positive 62 52.2 29 10.7 48 
Prior treatment      
Yes 91 91.2 49   
Resection 31  19   
LAT 47  15   
TACE 78  29   
HAIC 29     
Advanced vascular 
invasion 
     
Yes 18  36 36.0  
Extrapulmonary 
lesion(s) 
     
Yes 51 54.4 53 68.7 – 
Lymph node(s) 22 15.4 30 52 – 
Lung(s) 26 30.6 22 30.7 – 
Maximum tumor size 
(mm) 
34     
Range 7-170     
30 mm 59     
Stage *1 *2 *3 *3 *2 
I 1 1.2   0 
II 9 4.8   3 
III 30 20.7 B: 18 B: NE 31 
IV A 17 23 C: 82 C: 95.3 66 
IV B 43 47.6   
T-Bil (mg/dL)      
Median 0.8  0.7   
Range 0-7.7  0.1-16.4   
Alb (g/dL)      
Median 3.5  3.9   
Range 1.7-4.8  2.7-5.3   
AFP (ng/mL)      
Median 218  44.3   
Range 0.8-252150  0-2080000   
10 84   77.3 76 
*1 Japanese Classification of Liver Cancer; *2 UICC classification; *3 BCLC classification 
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Table 2: Incidence of drug-related adverse events with sorafenib therapy 
 

























HFSR 44 10 47.9 2.8 21.2 7.7 45.0 10.7 
Rash/ 
desquamation 
31 5 20.7 3.1 15.8 1.08 21.1 0.7 
Diarrhea 32 5 21.9 1.4 39.1 8.4 25.5 6.0 
Anorexia 27 4 13.8 1.9 13.8 0.3 12.8 0 
Hypertension 26 8 19.2 0.6 5.1 1.7 18.8 2.0 
Fatigue 24 2 4.6 0.6  – 20.1 3.4 
Alopecia 15 0 11.4 – 13.8 – 24.8 – 
Nausea 10 1 4.0 0.3 11.1 0.3 11.4 0.7 













AE incidence   
Total (%) G3/4 (%) Total (%) SARs (%) Total (%) G3/4 (%)
Leukopenia 43 8 1.9 0.3 0.3 0.3 
Neutropenia 37 6 0.9 0.2 – – 
Anemia 34 11 0.8 0.2 4.4 1.3 
Thrombocytopenia 56 12 8.5 0.9 1.7 0.7 
PT-INR 25 2 – – – – 
Elevated AST 70 25 1.4 – 1.7 1.7 
Elevated ALT 55 15 0.9 0.2 0.7 0.7 
Elevated ALP 35 5 0.3 – – – 
Elevated GTP 36 19 0.2 – – – 
Elevated T.Bil 53 11 2.6 0.2 0.7 – 
Elevated amylase 49 12 4.2 – – – 
Elevated lipase 78 37 3.7 – 1.3 – 
Elevated Cre 23 2 – – – – 
Hyponatremia 50 14 – – – – 
Hypokalemia 25 6 – – – – 
Hypocalcemia 55 1 – – – – 
Hypophosphatemia 66 29 3.6 0.5 34.9 10.5 
Hypoalbuminemia 48 5 1.1 – – – 




Table 4: Incidence of drug-related adverse events with sorafenib therapy 
 





Consultation to dermatologist 89 24 
Steroid ointment 89 38 
Emollient 91 69 
Hypotensive drug dose increased 90 21 
Intestinal drug 90 19 
Anti-diarrheal drug 89 16 




Table 5: Clinical laboratory tests recommended in proper use guidelines for sorafenib therapy7) 
Test/Test variable Cautionary AEs etc. Subjects Frequency/Duration 
Base
line
1 W 2 W 3 W 4 W 6 W 8 W 10 W12 W16 W20 W --- Post-
thera
py 
Hepatic function Hepatic impairment All patients ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○  ○
Pancreatic function Increased pancreatic 
function, pancreatitis 
All patients ○  ○  ○  ○  ○ ○ ○  ○
Blood count Neutropenia, 
thrombocytopenia, etc. 
All patients ○  ○  ○  ○  ○ ○ ○  ○
Serum phosphate Hypophosphatemia All patients ○  ○  ○  ○  ○ ○ ○  ○




All patients At hospital visit (simple HBP measurement once weekly (daily if 
possible)) 
Abdominal imaging GI perforation, 
pancreatitis  





Hemorrhage Patients on concomitant 






Reduced thyroid function Patients with specific 




(Chest x-ray, chest 
CT, KL-6) 
Interstitial pneumonia Patients with symptoms 

















OS (months)     
Median 11.0 10.7 6.5 9.2 
     
1-year SR (%)  45 44 – 59 
6-month SR 
(%) 
65 – 53 – 
     
PFS (months)  *    
Median 2.1 5.5 3.5 4.2/5.5 
     
Antitumor effect 
(%) 
§    
Total 
remission  
0 0 0 0 
Partial 
remission  
4 2 5 2 
Stable  45 71 46 34 
Tumor control 
rate 
49 43 53 – 
* Patients who died without confirmation of disease progression were excluded 
§ Patients not evaluated for therapeutic response were excluded. 
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Table 7: Factor analysis of tumor control with sorafenib therapy 
 
  n Tumor control rate 
(%) 
p * 
Age (years)     
 ≥65 137 49 0.75 
 <65 56 46  
Sex     
 Male 147 50 0.72 
 Female 43 47  
ECOG-PS     
 0 163 50 0.24 
 1-3 29 38  
Child-Pugh score     
 5 65 48 0.82 
 6 70 44  
 7 23 48  
 ≥8 10 60  
Child-Pugh class     
 A 135 46 0.52 
 B-C 33 56  
Prior treatment     
 Yes 173 48 0.87 
 None 18 50  
HBs antigens     
 Positive 36 50 0.91 
 Negative 149 49  
HCV antibodies     
 Positive 112 50 0.66 
 Negative 77 47  
Intrahepatic lesions     
 Yes 174 47 0.26 
 None 18 61  
Intrahepatic nodules     
 ≥5 95 40 0.058 
 <5 83 54  
Advanced vascular 
invasion 
    
 Yes 36 50 0.68 
 None 141 46  
Extrapulmonary 
lesion(s) 
    
 Yes 105 47 0.64 
 None 88 50  
Maximum tumor size 
(mm) 
    
 ≥30 108 47 0.79 
 <30 67 49  
Stage (Japanese 
Classification of Lung 
Cancer) 
    
 I-II 15 53 0.41 
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 III 53 57  
 IV A 31 39  
 IV B 84 46  
Initial dose     
 Normal dose 153 48 0.91 
 Reduction 39 49  
Baseline AFP     
 ≥10 151 43 0.021 
 <10 25 68  
Baseline PIVKA-II     
 ≥40 132 42 0.051 
 <40 40 60  
* Fisher's exact test 
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Randomized Phase II 
Trial28) 
(n=83) 
Total (%) G3/4 (%) Total (%) G3/4 (%) Total (%) G3/4 (%)
Leukopenia  38.2 5.1 51 0 41.0 1.2 
Neutropenia  20.1 5.1 63 19 53.0 8.4 
Eosinophilia  14.6 – 100 0 84.3 0 
Monocytosis  – – – – 57.8 0 
Lymphocytopoenia  – – 51 0 79.5 0 
Thrombocytopenia  32.1 9.3 44 0 50.6 1.2 
Increased AST 49.9 12.4 56 44 62.7 26.5 
Increased ALT  78.4 26.6 44 19 59 24.1 
Increased bilirubin  31.6 3.2 31 19 57.8 12.0 
Increased GTP  16.1 2.0 – – 49.4 0 
Increased ALP  12.3 0.2 44 0 30.1 1.2 
Elevated Cre 11.5 1.8 25 0 – 2.4* 
CTC-AE v3.0 Japan Society of Clinical Oncology Adverse Drug Reaction Criteria 
* Increased Cre data includes G2 patients 
 54 








Randomized Phase II 
Trial28) 
(n=83) 
Total (%) G3/4 (%) Total (%) G3/4 (%) Total (%) G3/4 (%)
Fever  81.3 0.2 94 0 96.4 3.6 
Biphasic fever 2.8  – – – – 
Anorexia 29.7  – – – – 
Abdominal pain 21.2 0 50 0 – – 
Nausea  18.8 0 25 0 – – 
Vomiting  13.5 0 – – 55.4 1.2 
Fatigue  9.3 0 – – 39.8 0 
Chills  0 – – 39.8 0 
Administration 
site pain  
21.2 0 50 0 43.4 0 
Diarrhea 2.0 0 31 0  – 
Ascites 1.2 0     
Hepatic failure 0.3 0.3     
Vascular injury   – – 0 0 




Table 10: Incidence of drug-related adverse events with miriplatin therapy (2) 
 
 Incidence (%) 
Ascites  1.2 
Liver abscess  0.6 




Table 11:  Incidence of drug-related adverse events with miriplatin therapy  
(Renal dysfunction) 
 




≤0.5 mg/dl 94.7% 97.5% 13.3% 
0.6-1.0 mg/dl 2.4% 1.7% 20.0% 
1.1-2.0 mg/dl 1.2% 0.2% 33.3% 
2.1-3.0 mg/dl 0.6% 0.0% 20.0% 















Total (%) G3/4 (%) Total (%) G3/4 (%) Total (%) G3/4 (%)
Fever  81.3 0.2 75.5 0 86.1 0.7 * 
Biphasic fever 2.8  2.5 – 5.1 – 
Anorexia 29.7 0.2 31.7 0 34.0 0.7 
Administration 
site pain 
21.2 0 25.6 0 15.3 0 
Nausea  18.8 0 21.4 0 12.5 0 * 
Vomiting  13.5 0 11.6 0 6.1 0 
Fatigue  9.3 0 12.2 0 10.3 0 
Diarrhea 2.0 0 1.8 0 1.0 0 
Ascites 1.2 0 0 0 3.0 0 
Hepatic failure 0.3 0.3 0.3 0.3 0 0 




Table 13: Comparison of clinical laboratory value anomalies with miriplatin therapy 










Total (%) G3/4 (%) Total (%) G3/4 (%) Total (%) G3/4 (%)
Leukopenia 38.2 5.1 18.2 3.3 25.2 5.8 
Neutropenia 20.1 5.1 17.3 3.6 23.4 5.8 
Eosinophilia 14.6 – 17.9  11.5  
Thrombocytopenia 32.1 9.3 30.9 5.8 30.2 13.7 *(G3)
Increased AST 49.9 12.4 45.2 13.5 50.7 19.4 
Increased ALT  78.4 26.6 81.0 28.8 70.3 28.3 * 
Increased bilirubin 31.6 3.2 26.1 0 46.0 5.8 * 
Increased GTP  16.1 2.0 15.8 2.6 14.5 0 
Increased ALP  12.3 0.2 12.7 0 10.1 0.7 
Elevated Cre 11.5 1.8 11.6 2.2 10.8 1.4 

























     
TE4 22.8 25.3 23.6 56 26.5 
TE3 24.3 26.7 20.8 6 25.3 
TE2 26.0 26.0 29.9 19 22.9 
TE1 16.6 12.5 17.4 19 20.5 
Not evaluated 10.3 9.6 8.3 0 4.8 
      
TE3+TE4 47.1 52.0 44.4 61 51.8 




Table 15: Independent factors contributing to effective (TE3/4) achievement with 
miriplatin therapy 
 
Factor Category Risk ratio 95% CI P 
Embolic material None 1  <0.001 
 Yes 3.66 2.13-6.29  
No. of tumors Single 1  0.017 
 2-3 1.01   
 4-9 0.66   
 ≥10 0.3 0.13-0.67  
Past history of TAE None 1  0.018 
 Yes 0.48 0.26-0.88  















 Total (%) G3/4 (%) Total (%) G3/4 (%) Total (%) G3/4 (%)
Fever  81.3 0.2 84.4 0.2 56.1 0 * 
Biphasic fever 2.8  3.0 – 0 – 
Anorexia 29.7 0.2 30.4 0.2 22.4 0 
Administration 
site pain 
21.2 0 22.2 0 13.8 0 
Nausea  18.8 0 20.1 0 4.0 0 
Vomiting  13.5 0 14.2 0 0 0 
Fatigue  9.3 0 9.2 0 – – 
Diarrhea 2.0 0 2.1 0 0 0 
Ascites 1.2 0 0.9 0 5.6 0 
Hepatic failure 0.3 0.3 0.3 0.3 0 0 




Table 17. Comparison of abnormal clinical laboratory values with or without embolic 
material during miriplatin therapy 
 








G3/4 (%) Total (%) G3/4 (%) Total (%) G3/4 (%)
Leukopenia 38.2 5.1 22.8 5.5 20.4 1.9 
Neutropenia 20.1 5.1 21.4 5.5 3.7 0 * 
Eosinophilia 14.6 – 14.8  11.8  
Thrombocytopenia 32.1 9.3 33.2 10.4 24.1 0 
Increased AST 49.9 12.4 52.8 19.3 25.9 8.6 * 
Increased ALT  78.4 26.6 78 24.5 81.5 44.4 * 
Increased bilirubin  31.6 3.2 32.1 3.3 27.8 0 
Increased GTP  16.1 2.0 16.1 1.8 14.8 3.7 
Increased ALP  12.3 0.2 12.6 0.2 9.3 0 
Elevated Cre 11.5 1.8 10.7 1.8 18.5 1.9 




Figure 1: Therapeutic efficacy of sorafenib 
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Figure 2: Therapeutic efficacy of miriplatin with or without embolus material 
 
 
 
 
 
